ifosfamide has been researched along with Li-Fraumeni Syndrome in 1 studies
Li-Fraumeni Syndrome: Rare autosomal dominant syndrome characterized by mesenchymal and epithelial neoplasms at multiple sites. MUTATION of the p53 tumor suppressor gene, a component of the DNA DAMAGE response pathway, apparently predisposes family members who inherit it to develop certain cancers. The spectrum of cancers in the syndrome was shown to include, in addition to BREAST CANCER and soft tissue sarcomas (SARCOMA); BRAIN TUMORS; OSTEOSARCOMA; LEUKEMIA; and ADRENOCORTICAL CARCINOMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teepen, JC | 1 |
| van Leeuwen, FE | 1 |
| Tissing, WJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| van der Pal, HJ | 1 |
| Loonen, JJ | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Neggers, SJCMM | 1 |
| Jaspers, MWM | 1 |
| Hauptmann, M | 1 |
| van der Heiden-van der Loo, M | 1 |
| Visser, O | 1 |
| Kremer, LCM | 1 |
| Ronckers, CM | 1 |
1 other study available for ifosfamide and Li-Fraumeni Syndrome
| Article | Year |
|---|---|
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |